Paper Details

  1. Home
  2. Paper Details

Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.

Author: ColemanCraig I, SobierajDiana M, WhiteC Michael

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Adding an inhaled corticosteroid (ICS) to a long-acting bronchodilator was associated with a reduced risk of exacerbations but an increased risk of pneumonia and oral candidiasis in patients with severe or very severe chronic obstructive pulmonary disease (COPD).
Paper Details　
Original Abstract of the Article :
BACKGROUND: Several clinical trials have evaluated the benefits associated with adding an inhaled corticosteroid (ICS) to a long-acting bronchodilator in the treatment of severe or very severe (stage III or IV) chronic obstructive pulmonary disease (COPD). OBJECTIVE: We conducted a meta-analysis to...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clinthera.2008.08.004

データ提供：米国国立医学図書館（NLM）

Inhaled Corticosteroids for COPD: Weighing the Benefits and Risks

The

respiratory system

is like a camel's lungs – essential for its ability to breathe and thrive. When this system is compromised, as in

chronic obstructive pulmonary disease

(COPD), it's crucial to find the best treatment approach. This study meticulously evaluates the benefits and risks of adding

inhaled corticosteroids

(ICS) to the treatment of severe or very severe COPD.

Navigating the Desert of COPD Treatment

The study, which involved a meta-analysis of nine randomized controlled trials, revealed that adjunctive ICS treatment can reduce the risk of exacerbations and improve patient-perceived health, but also increases the risk of pneumonia and oral candidiasis. Think of it as balancing the benefits of finding a refreshing oasis with the potential dangers of encountering a desert storm. The researchers emphasize that careful consideration is needed when deciding whether to add ICS to COPD treatment.

Managing COPD: A Balancing Act

If you're diagnosed with COPD, it's important to discuss your treatment options with your doctor. They can help you weigh the potential benefits and risks of different therapies and create a personalized plan that meets your individual needs. Remember, just as a camel adapts to the changing desert landscape, managing COPD requires a flexible approach and a willingness to adjust the course as needed.

Dr.Camel's Conclusion

This study highlights the complexity of COPD treatment, emphasizing the need for a tailored approach that considers both the benefits and risks of different therapies. Navigating the desert of COPD requires careful observation, informed decision-making, and a commitment to achieving a balance between symptom relief and overall well-being.

Date :
  1. Date Completed 2008-10-20
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

18803985

DOI: Digital Object Identifier

10.1016/j.clinthera.2008.08.004

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.